Dougherty J A, Rhoney D H
Pharmacy Practice, College of Pharmacy & Allied Health Professions, Wayne State University, Detroit, Ml, USA.
Neurol Res. 2001 Dec;23(8):821-9. doi: 10.1179/016164101101199414.
Gabapentin is an anti-epileptic drug (AED) that was approved in 1993 for the adjunct treatment of complex partial seizures (CPS) with and without generalization. Although the mechanism of action of gabapentin has not been fully elucidated, it has been shown to be effective not only as an adjunct AED in patients with CPS, but also in children with epilepsy, many pain syndromes (most notably neuropathic pain), and several other neurological diseases. The efficacy of the drug as an AED In both adults and children has been mostly seen when used as an adjunct with other AEDs. When used as monotherapy, it has been most effective for CPS in adults at higher doses. Gabapentin as monotherapy in children has not been shown to be as beneficial as in adults. Also, the dosing of the drug in children has been complicated by negative behavioral adverse effects. Overall, gabapentin has a low incidence of adverse effects, a pharmacokinetic profile that limits its drug interactions, and limited effects on cognition when compared to traditional AEDs. The dosing of the drug is dependent on the disease state targeted, the number of specific therapeutic drugs used, and the renal function of the patient.
加巴喷丁是一种抗癫痫药物（AED），于1993年被批准用于辅助治疗伴有或不伴有泛化的复杂部分性发作（CPS）。尽管加巴喷丁的作用机制尚未完全阐明，但已证明它不仅作为CPS患者的辅助抗癫痫药物有效，而且对癫痫儿童、许多疼痛综合征（最显著的是神经性疼痛）以及其他几种神经系统疾病也有效。该药物作为抗癫痫药物在成人和儿童中大多与其他抗癫痫药物联合使用时才显示出疗效。作为单一疗法使用时，在较高剂量下对成人的CPS最有效。加巴喷丁作为儿童单一疗法尚未显示出与成人一样有益。此外，该药物在儿童中的给药因负面行为不良反应而变得复杂。总体而言，与传统抗癫痫药物相比，加巴喷丁的不良反应发生率低，其药代动力学特征限制了药物相互作用，对认知的影响也有限。该药物的给药取决于所针对的疾病状态、所用特定治疗药物的数量以及患者的肾功能。
